CABAZITAXEL | N207970 | ACTAVIS LLC AN INDIRECT WHOLLY OWNED SUB OF TEVA PHARMACEUTICALS USA INC
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Sanofi-Aventis U.S. LLC, et al. v. Sandoz Inc. 2 patentsANDA 207736, 207619, 207718, 207591cabazitaxel | D. Del. | 2020-06-12 | Terminated 2023-07-05 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from ProPharma FDA-2026-P-3104 Amneal Pharmaceuticals Inc., through ProPharma, filed this citizen petition requesting that the FDA determine that CABAZITAXEL injection for intravenous use 60 mg/6 mL (10 mg/mL) under NDA 207970 held by Actavis LLC was not discontinued for reasons of safety or effectiveness, to permit Amneal to rel | 505(q) | 2026-03-25 | Open | ProPharma |
Source: Regulations.gov. FDA citizen petitions matched by application number.
No patent or exclusivity listings for this strength.